Josh Ismin & Dr Sam Banister — CEO & Chief Scientific Officer at Psylo
About Josh & Sam
Josh Ismin & Dr Sam Banister and the co-founders of Psylo.
Psylo is a biotech company developing medications inspired by psychedelics found in nature. With the goal to produce next-generation neuropsychiatric therapeutics which are accessible to a broader patient population. Psylo is based at the University of New South Wales, and was recently named a Top 100 Innovator.
-
Josh Ismin is former Microsoft employee and a repeat founder with extensive fundraising and operational experience across a number of tech start-ups. He holds an MBA and BSBA from Washington University in St Louis.
And Dr Samuel Banister holds a PHD from Sydney University and completed his post-doc at Stanford University, developing a new clinical candidate for ALS leading to the formation of Tranquis Therapeutics. In addition to consulting for a number of biotech startups Sam spent several years as the Team Leader in Medicinal Chemistry with The Lambert Initiative for Cannabinoid Therapeutics at University of Sydney.
-